The in vivo efficacy of Ctx-VY and Ctx-Y104D was maintained in the S492R-EGFR-COLO320DM xenograft model; however, there was no significant difference between the cetuximab group and the PBS group in tumor growth suppression (Fig. 7m–o). Here, EGFR is linked to neoplasm.